UB Paderborn / Katalog / Suche / in CDI

DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents

Molecules (Basel, Switzerland), 2016-12, Vol.21 (12), p.1741-1741

2016

Volltextzugriff (PDF)

A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin

The Journal of urology, 2012-11, Vol.188 (5), p.1712-1718

2012

Volltextzugriff (PDF)

Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance

Journal of immunotherapy (1997), 2016-04, Vol.39 (3), p.117

2016

Volltextzugriff (PDF)

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

Drug design, development and therapy, 2008, Vol.2, p.105

Spearman, Maureen

2008

Volltextzugriff (PDF)

Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin

Journal of immunotherapy, 2009-07, Vol.32 (6), p.574-584

2009

Volltextzugriff (PDF)

Abstract 2963: VB7-756: a Her2-specific diabody armed with deBouganin, a plant toxin with a distinct MOA

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2963-2963

2016

Volltextzugriff (PDF)

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

Drug design, development and therapy, 2010-11, Vol.4 (default), p.313-320

2010

Volltextzugriff (PDF)

Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential

Cancer biotherapy & radiopharmaceuticals, 2012-11, Vol.27 (9), p.582

2012

Volltextzugriff (PDF)

Development of a GMP Phase III purification process for VB4-845, an immunotoxin expressed in E. coli using high cell density fermentation

Protein expression and purification, 2011-07, Vol.78 (1), p.27-37

2011

Volltextzugriff (PDF)

A targeted proteomic approach for the identification of tumor-associated membrane antigens using the ProteomeLab ™ PF-2D in tandem with mass spectrometry

Biochemical and biophysical research communications, 2006-09, Vol.348 (3), p.1055-1062

2006

Volltextzugriff (PDF)

Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration

Cancer biotherapy & radiopharmaceuticals, 2009-08, Vol.24 (4), p.477

2009

Volltextzugriff (PDF)

Fusogenics: a recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments

Journal of biomolecular screening, 2011-01, Vol.16 (1), p.90-100

2011

Volltextzugriff (PDF)

The Role of Environmental Antigens in the Spontaneous Development of Autoimmunity in MRL-lpr Mice

The Journal of immunology (1950), 1999-06, Vol.162 (11), p.6322-6330

1999

Volltextzugriff (PDF)

Abstract 2388: In vitro assessment of tumor associated I.O. markers in cancer cell lines following Vicinium treatment

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2388-2388

2019

Volltextzugriff (PDF)

Abstract 2788: VB6-845d tumor cell killing elicits biologic features of immunogenic cell death

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2788-2788

2018

Volltextzugriff (PDF)

Abstract 79: Trastuzumab and C6.5 diabody armed with deBouganin overcome drug resistance to ADCs comprised of anti-microtubule agents

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.79-79

2017

Volltextzugriff (PDF)

Abstract 5770: Engineering and characterization of anti-PSMA humabody-deBouganin fusion proteins

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5770-5770

2018

Volltextzugriff (PDF)

Abstract 2961: deBouganin conjugated to trastuzumab overcomes multiple mechanisms of T-DM1 drug resistance

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2961-2961

2016

Volltextzugriff (PDF)

Differential Control of Autoantibodies and Lymphoproliferation by Fas Ligand Expression on CD4+ and CD8+ T Cells In Vivo

The Journal of immunology (1950), 1999-09, Vol.163 (6), p.3138-3142

1999

Volltextzugriff (PDF)

Effective tumor targeting: strategies for the delivery of Armed Antibodies

Current opinion in drug discovery & development, 2005-03, Vol.8 (2), p.177

2005

Volltextzugriff (PDF)

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients

Drug design, development and therapy, 2010-11, Vol.4, p.313-320

2010

Volltextzugriff (PDF)

A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

Drug design, development and therapy, 2009-02, Vol.2, p.105-114

2009

Volltextzugriff (PDF)

Depletion of natural killer cells from the graft reduces interferon-gamma levels and lipopolysaccharide-induced tumor necrosis factor-alpha release in F1 hybrid mice with acute graft-versus-host disease

Transplantation, 1998-08, Vol.66 (3), p.284

1998

Volltextzugriff (PDF)

B cell genotype determines the fine specificity of autoantibody in lpr mice

The Journal of immunology (1950), 1997-07, Vol.159 (2), p.1027

1997

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents

A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin

Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin

Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation

Abstract 2963: VB7-756: a Her2-specific diabody armed with deBouganin, a plant toxin with a distinct MOA

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential

Development of a GMP Phase III purification process for VB4-845, an immunotoxin expressed in E. coli using high cell density fermentation

A targeted proteomic approach for the identification of tumor-associated membrane antigens using the ProteomeLab ™ PF-2D in tandem with mass spectrometry

Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration

Fusogenics: a recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments

The Role of Environmental Antigens in the Spontaneous Development of Autoimmunity in MRL-lpr Mice

Abstract 2388: In vitro assessment of tumor associated I.O. markers in cancer cell lines following Vicinium treatment

Abstract 2788: VB6-845d tumor cell killing elicits biologic features of immunogenic cell death

Abstract 79: Trastuzumab and C6.5 diabody armed with deBouganin overcome drug resistance to ADCs comprised of anti-microtubule agents

Abstract 5770: Engineering and characterization of anti-PSMA humabody-deBouganin fusion proteins

Abstract 2961: deBouganin conjugated to trastuzumab overcomes multiple mechanisms of T-DM1 drug resistance

Differential Control of Autoantibodies and Lymphoproliferation by Fas Ligand Expression on CD4+ and CD8+ T Cells In Vivo

Effective tumor targeting: strategies for the delivery of Armed Antibodies

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients

A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

Depletion of natural killer cells from the graft reduces interferon-gamma levels and lipopolysaccharide-induced tumor necrosis factor-alpha release in F1 hybrid mice with acute graft-versus-host disease

B cell genotype determines the fine specificity of autoantibody in lpr mice

Suchergebnisse filtern